Harrow, Inc.
Every calculator, already run for HROW
Open the full toolkit →You have the numbers on HROW. Get the argument.
A written report on which of these readings actually decide the outcome for Harrow, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
9 analysts covering HROWAnalyst Price Target Disagreement for Harrow, Inc.
Wall Street's bull case implies +166% from the current price; the bear case implies +36%. A 130% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for HROW
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Harrow, Inc.
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE, as well as BYQLOVI; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract surgery; BYOOVIZ, a LUCENTIS biosimilar indicated for the treatment of patients with Neovascular (Wet) a…
HROW — frequently asked
Is HROW a buy right now?
Wall Street's consensus rating on Harrow, Inc. is Strong Buy across 9 analysts, with a mean price target of $65.00 (+96% vs. the current $33.08). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
When is HROW's next earnings date?
Harrow, Inc. is next scheduled to report earnings around Nov 9, 2026. A full HROW research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Harrow, Inc.?
Analysts covering Harrow, Inc. (HROW) range from a bear-case target of $45.00 to a bull-case high of $88.00, with a mean consensus target of $65.00 across 9 analysts. The spread of $43.00 (130% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Harrow, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Harrow, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full HROW research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Harrow, Inc., in minutes. 3 free reports included with every account — no credit card required.